NEW YORK (GenomeWeb News) – Agilent Technologies disclosed in a filing with the US Securities and Exchange Commission today that it will undertake a targeted restructuring that will result in the firm cutting 300 positions from its temporary workforce and 500 positions from its regular global workforce.
 
The firm did not disclose which parts of the company would be affected by the cuts or whether they would specifically target its Bio-Analytical Measurement unit or its Electronic Measurement unit.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.